Clinical pharmacology and pharmacogenetics of gemcitabine. - Wikidata - wikimedia - TriplyDB

Clinical pharmacology and pharmacogenetics of gemcitabine.

Clinical pharmacology and pharmacogenetics of gemcitabine.

http://www.wikidata.org/entity/Q34985979

about

Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies PharmGKB summary: gemcitabine pathway Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Enhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.The role of transporters in the toxicity of nucleoside and nucleotide analogs.An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.Human cytidine deaminase: a biochemical characterization of its naturally occurring variants.Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.Genotypes Affecting the Pharmacokinetics of Anticancer Drugs.Drug transporter pharmacogenetics in nucleoside-based therapies.Germline genetic markers for urinary bladder cancer risk, prognosis and treatment response.Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?Pharmacogenomics in the treatment of lung cancer: an update.S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro.HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.Liver kinase B1 enhances chemoresistance to gemcitabine in breast cancer MDA-MB-231 cells.Molecular predictors of gemcitabine response in pancreatic cancer.One SNP for both cancer risk and survival in colorectal cancer: two for the price of one?N-acetyl-L-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway.Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells.Pancreatic Cancer Chemoresistance to Gemcitabine.Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.Contribution of CNT1 and ENT1 to ribavirin uptake in human hepatocytes.Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation.

P2860

Q26752368-4F577CD7-DDA8-4432-8ABB-DE17C94E37C0 Q28476738-D6265338-A0BE-423A-A741-0F1D29742F80 Q28481440-0B15B631-4EA5-445E-A165-7AA9BF6EBE9B Q28487715-9DBC0632-2CD5-4B6D-BEB9-0C34CCBC6CC3 Q28535154-71CB13F9-3409-4474-9CBD-A5F391D3C625 Q34435450-E6231747-F422-4559-B4F6-2D2CEBA44DC0 Q34555685-88EB1F42-5861-4CF5-8EDF-5134E2AE737A Q34609029-CB764703-35D4-4E5D-9BC7-7FE421C70241 Q34621614-A716495B-2A7D-41B1-87DD-F5F6F56F17EF Q35675274-F04A1BC8-9AC4-4534-A2A0-143D70EAEDC5 Q36094941-8726D265-EDAD-4CEB-9137-3AE466DD00FE Q36342657-E05FEBF6-9DBF-4EC6-A1ED-4DEB058EF18A Q36493132-DB54071E-5873-470B-94B0-C4DEC6B06F29 Q36919830-F799287C-C168-4032-B5B5-24DBDDDAFD36 Q36921993-5D902767-2AE6-4332-8ACC-D7F5B45ECBD6 Q37175159-EB11587A-FEFD-470E-8440-0748B5F27635 Q37207004-1C36287C-4A96-4F64-B13A-225D143CDDEE Q37268613-614CBB57-287A-465B-BD01-4C7D1CB84AC2 Q37507420-42267867-A994-4D09-B4DD-40F4A43890C0 Q37523862-D9A6DD4C-B650-4F02-A2EE-7BC6D3F4DAD7 Q37662007-5A1A9EBE-E3D6-4955-8686-692E55A2B5FF Q37685527-5965DFC7-2894-4FA4-BE88-D58CC93977BC Q37760954-6EFD2FC4-DE9C-4732-B724-6A4608726488 Q37797468-977A7367-3C69-400B-8FE3-CBA3F594B4FD Q37963498-B062C49B-C8D5-4E7D-8723-79B76A41AA24 Q38591731-A59D7D35-E46A-4672-AB4B-BD31C982464B Q38596926-20687271-C5F1-404B-849F-0E5E22E6428E Q38805485-258F8F42-B024-465F-92A7-93256AE9E1EC Q38811283-B2176970-22CF-4DCD-8636-CD09DCF8CDF4 Q38949772-6E4C4168-5E76-4584-8678-4950FDA75A37 Q39250668-2FC7346A-1773-4CBD-A268-A0A6A8A692C8 Q42125506-44363D49-505B-46E5-86E8-3121599E085D Q42544690-1B55874E-04BA-4AC9-A96A-D1179DCBA40C Q42717833-CCCF02E2-9F36-422B-9186-D04DF9AB2638 Q47135556-2133D07F-6467-4429-B916-C9409E5B878F Q47965783-7599F4B3-E27D-4DAB-9874-1ED771CD4DAC Q48598500-33EEFCAE-AB06-459E-B7E6-1CAF5C714AA6 Q49387560-46695615-ACFF-45A4-959F-3B086DE4D95F Q49929146-9CACA4C5-A5F4-4070-8ED5-A57BBFF3A2D0 Q50053693-219CEC49-00DB-4404-AD00-C711303F6F19

P2860

Clinical pharmacology and pharmacogenetics of gemcitabine.

http://www.wikidata.org/entity/Q34985979

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical pharmacology and pharmacogenetics of gemcitabine.

@ast

Clinical pharmacology and pharmacogenetics of gemcitabine.

@en

Clinical pharmacology and pharmacogenetics of gemcitabine.

@nl

type

label

Clinical pharmacology and pharmacogenetics of gemcitabine.

@ast

Clinical pharmacology and pharmacogenetics of gemcitabine.

@en

Clinical pharmacology and pharmacogenetics of gemcitabine.

@nl

prefLabel

Clinical pharmacology and pharmacogenetics of gemcitabine.

@ast

Clinical pharmacology and pharmacogenetics of gemcitabine.

@en

Clinical pharmacology and pharmacogenetics of gemcitabine.

@nl

P1433

Q34985979-056EF478-1016-48F7-A183-EED1E3607903

P1476

Q34985979-029C2548-CB81-4322-BAB6-272C938E2F49

P2093

Q34985979-6BF001FA-B4B1-43EB-BB34-3F7B8D0A8FAD

Q34985979-C9B7DAA6-3207-4F21-BCEA-D26F3470C292

Q34985979-F501C0B8-C9C0-481D-8C72-25B037AA7A28

Q34985979-FC40F2C8-7134-4249-8E49-99CF791D501A

P2860

Q34985979-114B8FF5-018A-4AAC-82F1-1653F6315F48

Q34985979-13B4F1E3-8E6D-49F0-861E-B1B40201F7CE

Q34985979-1A1F595F-6F3C-4C1C-93B1-9B6F177695D4

Q34985979-243CEBD8-46E5-4024-BEB9-DCBE3C149954

Q34985979-24CAB9F5-D348-4E77-B7B6-160475ABC93F

Q34985979-267BEC63-CDC2-44CB-8206-823F13F3B633

Q34985979-29412D25-487F-4F29-B899-BEB0886B61C0

Q34985979-3957C068-C86A-4D1D-9025-B0E4F7ECB435

Q34985979-39CB3304-8EE8-4534-B45B-C9F1E4EF4515

Q34985979-3DFDCB1C-E558-417D-80DD-45969CEC6B4C

P304

Q34985979-CF8BA3C4-4ABC-4BF3-AC7E-EE2CB6092631

P31

Q34985979-F1A3D32B-1C4E-4B93-A0A8-FA1B482B5AD5

P356

Q34985979-493998F3-2900-46BC-8A01-AF4FAD9E8707

P407

Q34985979-73D65130-5CFE-4D31-B42F-0BA13FB9A96A

P433

Q34985979-8BBCF0D8-4D51-4D95-96BA-222A70A310E9

P478

Q34985979-AB812CAA-23FE-470A-87C5-A5A87D74A458

P577

Q34985979-9981C764-23AF-4285-AC9C-0B3BD1973737

P698

Q34985979-14D34B43-E411-403A-8D2F-34CEED514C66

P921

Q34985979-66DC0E11-9A47-4CF7-9890-DFDA681E21E0

P356

03602530902741828

P1433

Drug Metabolism Reviews

P1476

Clinical pharmacology and pharmacogenetics of gemcitabine.

@en

P2093

Andrea Wong

http://www.w3.org/2001/XMLSchema#string

Federico Innocenti

http://www.w3.org/2001/XMLSchema#string

Ross A Soo

http://www.w3.org/2001/XMLSchema#string

Wei-Peng Yong

http://www.w3.org/2001/XMLSchema#string

P2860

Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.

Pharmacogenomics--drug disposition, drug targets, and side effects.

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.

Functional and genetic diversity in the concentrative nucleoside transporter, CNT1, in human populations.

P304

77-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03602530902741828

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19514966

http://www.w3.org/2001/XMLSchema#string

P921